Showing results (211-220 of 830) with videos related to
Sort By:
Pageof 83
Pharmacogenetics|November 24, 1998
In-vitro characterization of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidolL P Pan, C De Vriendt, F M BelpairePharmacogenetics|November 24, 1998
Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotypingA D Kashuba, A N Nafziger, G L Kearns, et al.Pharmacogenetics|April 1, 1996
Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlationsU Fuhr, K L Rost, R Engelhardt, et al.Pharmacogenetics|April 1, 1996
Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populationsC Deloménie, L Sica, D M Grant, et al.Pharmacogenetics|December 1, 1996
Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizersJ A Agúndez, M Olivera, J M Ladero, et al.Pharmacogenetics|December 1, 1996
Imipramine metabolism in relation to the sparteine oxidation polymorphism--a family studyH Madsen, T S Hansen, K BrøsenPharmacogenetics|August 1, 1996
Exon and intron variants in the human tryptophan 2,3-dioxygenase gene: potential association with Tourette syndrome, substance abuse and other disordersD E Comings, R Gade, D Muhleman, et al.Pharmacogenetics|August 1, 1996
Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotypeA K Daly, K S Fairbrother, O A Andreassen, et al.Pharmacogenetics|June 1, 1993
The paraoxonase polymorphism in a Saudi Arabian populationC P Nogueira, D A Evans, B N La DuPharmacogenetics|June 1, 1996
A fluvoxamine-caffeine interaction studyU Jeppesen, S Loft, H E Poulsen, et al.Pageof 83